48
Participants
Start Date
May 19, 2023
Primary Completion Date
October 14, 2024
Study Completion Date
October 25, 2024
Sparsentan
Target dose of 400 mg daily
Travere Investigational Site, New York
Travere Investigational Site, Fresh Meadows
Travere Investigation SIte, Clifton Park
Travere Investigational Site, Philadelphia
Travere Investigational Site, Jacksonville
Travere Investigational Site, New Bern
Travere Investigational Site, Columbia
Travere Investigational Site, Birmingham
Travere Investigational Site, Louisville
Travere Investigational Site, Columbus
Travere Investigational Site, Fort Wayne
Travere Investigational Site, Chicago
Travere Investigational Site, Evergreen Park
Travere Investigational Site, Kansas City
Travere Investigational Site, Shreveport
Travere Investigational Site, Dallas
Travere Investigational Site, Dallas
Travere Investigational Site, Denver
Travere Investigational Site, Chubbuck
Travere Investigational Site, Idaho Falls
Travere Investigational Site, Boise
Travere Investigational Site, Albuquerque
Travere Investigational Site, Glendale
Travere Investigational Site, Chula Vista
Travere Investigational Site, Garden Grove
Travere Investigational Site, Hong Kong
Travere Investigational Site, Kowloon
Travere Investigational Site, Shatin
Travere Investigational Site, Sheung Wan
Travere Investigational Site, Tsuen Wan
Travere Therapeutics, Inc.
INDUSTRY